Gefitinib Versus Placebo in Completely Resected Non–Small-Cell Lung Cancer: Results of the NCIC CTG BR19 Study

PURPOSE: Survival of patients with completely resected non–small-cell lung cancer (NSCLC) is unsatisfactory, and in 2002, the benefit of adjuvant chemotherapy was not established. This phase III study assessed the impact of postoperative adjuvant gefitinib on overall survival (OS). PATIENTS AND METH...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Goss, Glenwood D., O'Callaghan, Chris, Lorimer, Ian, Tsao, Ming-Sound, Masters, Gregory A., Jett, James, Edelman, Martin J., Lilenbaum, Rogerio, Choy, Hak, Khuri, Fadlo, Pisters, Katherine, Gandara, David, Kernstine, Kemp, Butts, Charles, Noble, Jonathan, Hensing, Thomas A., Rowland, Kendrith, Schiller, Joan, Ding, Keyue, Shepherd, Frances A.
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Clinical Oncology 2013
Assuntos:
ORIGINAL REPORTS
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3770864/
https://ncbi.nlm.nih.gov/pubmed/23980091
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2013.51.1816
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares